Get the Stockscreener App
133.66
0.69%
0.91
After Hours:
130.99
-2.67
-2.00%
Neurocrine Biosciences Inc stock is traded at $133.66, with a volume of 510.04K.
It is up +0.69% in the last 24 hours and up +6.25% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$132.75
Open:
$133.275
24h Volume:
510.04K
Relative Volume:
0.45
Market Cap:
$13.23B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
45.31
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+0.13%
1M Performance:
+6.25%
6M Performance:
-9.43%
1Y Performance:
-8.10%
1-Day Range:
$133.10
$134.13
1-Week Range:
$131.12
$135.70
52-Week Range:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
133.66 | 13.14B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
What analysts say about Neurocrine Biosciences Inc. stockDynamic investment opportunities - Autocar Professional
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Neurocrine Bio. stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada
What drives Neurocrine Biosciences Inc. stock priceAccelerated investment success - Autocar Professional
Neurocrine Biosciences Inc. Stock Analysis and ForecastBreakthrough profits - Autocar Professional
Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN
Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Truist Financial - MarketBeat
Is Neurocrine Biosciences Inc. a good long term investmentExplosive capital gains - Autocar Professional
Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st
Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks
Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.
Neurocrine reports positive results from Crenessity trial - MSN
Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest
Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance
Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan
Neurocrine shares registry data showing CAH treatment challenges - StreetInsider
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 - PR Newswire
New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter
Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener
What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru
NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq
Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com
Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛
Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting - Eastern Progress
Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference - StreetInsider
Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 - Nasdaq
Neurocrine Biosciences: CRENESSITY's Breakthrough in CAH Positions NBIX for Sustained Growth - AInvest
Neurocrine reports positive results from Crenessity trial (NBIX) - Seeking Alpha
Neurocrine reports positive one-year data for CAH treatment By Investing.com - Investing.com India
Neurocrine presents one-year data from study of Crenessity - TipRanks
CRENESSITY's Groundbreaking CAH Data Positions Neurocrine Biosciences for Dominance in a High-Impact Market - AInvest
Neurocrine reports positive one-year data for CAH treatment - Investing.com
New Clinical Data: CRENESSITY Achieves Breakthrough 30% Steroid Reduction in Adult CAH Treatment - Stock Titan
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 - PR Newswire
Neurocrine Biosciences (NASDAQ:NBIX) Given New $174.00 Price Target at UBS Group - MarketBeat
Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock - Investing.com Australia
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):